RecruitingPhase 2NCT05088226

Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chinese PLA General Hospital
Principal Investigator
Daihong Liu
Chinese PLA General Hospital
Intervention
Ruxolitinib combined with Chidamide.(drug)
Enrollment
50 enrolled
Eligibility
12-65 years · All sexes
Timeline
20212031

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05088226 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials